TORONTO, ONTARIO / ACCESSWIRE / April 22, 2014 / Theralase Technologies Inc. (TLT.V) (TLTFF:OTCBB) announced today that its Photo Dynamic Compound (PDC) technology, proven effective in the destruction of bacteria and cancer, has been peer reviewed and approved for presentation at the renowned International Conference on Laser Applications in Life Sciences to take place in Ulm, Germany in June 2014.
Theralase's ability to destroy two types of bacteria (Staphylococcus aureus and Methicillin Resistant Staphylococcus aureus (MRSA)) up to 99.99999% with a new class of PDCs has caught the attention of the global scientific and medical community after recent publication in the journal Photodiagnosis and Photodynamic Therapy.
The latest Theralase research is considered pivotal by the international community because the PDCs were able to destroy two types of bacteria in both normal and low oxygenated tissue in nanomolar concentrations (micrograms of the PDCs were lethal to bacteria when light activated) and were proven especially effective in low oxygen environments, where certain types of bacteria and cancer thrive.
Dr. Arkady Mandel, Chief Scientific Officer of Theralase stated that, "Theralase's PDC technology addresses the challenge of bacteria that develop an immunity to destruction due to an acquired resistance to treatment, such as antibiotic drugs. The latest research confirms that the Theralase PDCs are a reliable alternative to antibiotics and have none of the acquired resistance limitations. This new approach provides a novel and effective treatment to destroying bacteria by improving selectivity, reducing treatment time and improving safety for clinical applications, which is critical for a broad international acceptance of the technology. Moreover, the fact that the Theralase PDCs are effective in low oxygen and have a higher stability than FDA approved PDCs may have a tremendous impact in limiting the further spread of antibiotic-resistant strains of bacteria and simultaneously provide superior health care worldwide."
Roger Dumoulin-White, President and CEO of Theralase stated that, "I am delighted that our research in PDCs has attracted the international attention of the scientific and medical community. By being extremely effective in microgram concentrations, Theralase now has the opportunity for early partnership with large pharmaceutical organizations interested in alternatives to antibiotics for bacteria destruction. This is a billion dollar market in need of technology that is able to eliminate the bacterial load quickly and effectively, while minimizing risk to the patient."
About Theralase Technologies Inc.
Theralase Technologies Inc. designs, manufactures and markets patented, superpulsed laser technology used in eliminating pain and destroying cancer. Theralase technology is safe and effective in eliminating pain, reducing inflammation and accelerating tissue regeneration of numerous nerve, muscle and joint conditions. Theralase is actively developing patented technology that is able to target and destroy cancers, bacteria and viruses when light activated.
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.
For More Information:
President & CEO
Theralase Technologies Inc.
1.866.THE.LASE (843-5273) ext. 225
416.699.LASE (5273) ext. 225
SOURCE: Theralase Technologies Inc.